Pfizer nabs $13.5B in U.S. bond issue

No one can accuse Pfizer leadership of timidity. With the nation mired in a deep recession, the company Tuesday launched the second largest U.S.-dollar bond issue in history, a $13.5 billion offering to help fund its $68 billion acquisition of Wyeth. (It's exceeded only by Roche's recent $16 billion for its Genentech buy.) Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.